PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.85%
Negative revenue growth while CVE stands at 6.64%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.81%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-99.24%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-99.62%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-111.83%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-111.92%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-111.46%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.95%
Slight or no buybacks while CVE is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-1.40%
Reduced diluted shares while CVE is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.94%
Dividend reduction while CVE stands at 4.21%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-0.20%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-3.31%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-45.62%
Negative 10Y revenue/share CAGR while CVE stands at 45.24%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
37.22%
5Y revenue/share CAGR under 50% of CVE's 111.42%. Michael Burry would suspect a significant competitive gap or product weakness.
-35.73%
Negative 3Y CAGR while CVE stands at 14.53%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
118.92%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
37.14%
Below 50% of CVE's 84.53%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
35.18%
3Y OCF/share CAGR above 1.5x CVE's 1.83%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-116.97%
Negative 10Y net income/share CAGR while CVE is at 112.83%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-881.48%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-104.25%
Negative 3Y CAGR while CVE is 139.22%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-40.25%
Negative equity/share CAGR over 10 years while CVE stands at 21.12%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
2.11%
Below 50% of CVE's 4.29%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
99.68%
3Y equity/share CAGR above 1.5x CVE's 38.21%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-12.61%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
206.22%
Similar 5Y dividend/share CAGR to CVE's 204.16%. Walter Schloss sees parallel philosophies in mid-term capital returns.
112.49%
Below 50% of CVE's 389.00%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-17.21%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
No Data
No Data available this quarter, please select a different quarter.
-72.85%
Negative asset growth while CVE invests at 3.40%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-3.96%
We have a declining book value while CVE shows 1.78%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-7.13%
We’re deleveraging while CVE stands at 6.98%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
16.67%
SG&A growth well above CVE's 16.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.